(De-)assetizing pharmaceutical patents: Patent contestations behind a blockbuster drug-Reference-Cited by-同舟云学术

(De-)assetizing pharmaceutical patents: Patent contestations behind a blockbuster drug

Published:2021-12-07 Issue:1 Volume:51 Page:23-45
ISSN:0308-5147
Container-title:Economy and Society
language:en
Short-container-title:Economy and Society

Author:

Bourgeron Théo,Geiger Susi^ORCID

Funder

European Research Council

Publisher

Informa UK Limited

Subject

General Social Sciences,Economics and Econometrics,History

Link

https://www.tandfonline.com/doi/pdf/10.1080/03085147.2022.1987752

Reference66 articles.

1. Anason, D. (1996, August 5). Emory and Glaxo escalate war over hottest AIDS drug. Atlanta Business Chronicle. Retrieve from https://www.bizjournals.com/atlanta/stories/1996/08/05/story2.html

2. Bio-pharma: A financialized business model

3. Access to Medicines Activism

4. Pharmaceutical Matters

5. Berkrot, B. (2011, November 23). Gilead could have had Pharmasset cheap. Reuters.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Countermovements from the core: the assetization of pharmaceuticals, transparency activism and the access to medicines movement;Socio-Economic Review;2024-05-30

3. Venture capital, the fetish of artificial intelligence, and the contradictions of making intangible assets;Economy and Society;2024-01-02

4. Social Forms Beyond Value: Public Wealth and Its Contradictions;Critical Sociology;2023-11-25

5. The knowledge-leveraging corporation in the neoliberalisation-financialisation nexus;Competition & Change;2023-11-08